Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley [Yahoo! Finance]
Arcellx, Inc. (ACLX)
Company Research
Source: Yahoo! Finance
Following BYSANTI's approval, the firm's revenue model for Vanda has been updated, reflecting expected growth in the psychiatry franchise with peak BYSANTI sales now included and probability adjustments removed, the analyst tells investors in a research note. Base assumptions include mid-to-high single-digit quarter over quarter growth in BYSANTI/FANAPT prescriptions through 2026, the firm says. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now See Insiders' Hot Stocks on TipRanks Read More on VNDA: Disclaimer & Disclosure Report an Issue Vanda announces FDA accepted BLA for imsidolimab Midday Fly By: Trump ups worldwide tariff to 15%, Gilead buying Arcellx Unusually active option classes o
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal [Yahoo! Finance]Yahoo! Finance
- Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders?PR Newswire
- Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLXBusiness Wire
- How Renewed Wall Street Optimism Around HIV, Oncology And IP Runway At Gilead Sciences (GILD) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (GILD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
ACLX
Earnings
- 2/26/26 - Miss
ACLX
Sec Filings
- 3/6/26 - Form SC
- 3/6/26 - Form SC
- 3/6/26 - Form SCHEDULE
- ACLX's page on the SEC website